Cargando…

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report

RATIONALE: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li-Xin, Chen, Xiaoping, Jia, Mingming, Wang, Shengdian, Shen, Jianliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916644/
https://www.ncbi.nlm.nih.gov/pubmed/29668614
http://dx.doi.org/10.1097/MD.0000000000010455
_version_ 1783317050510278656
author Wang, Li-Xin
Chen, Xiaoping
Jia, Mingming
Wang, Shengdian
Shen, Jianliang
author_facet Wang, Li-Xin
Chen, Xiaoping
Jia, Mingming
Wang, Shengdian
Shen, Jianliang
author_sort Wang, Li-Xin
collection PubMed
description RATIONALE: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. PATIENT CONCERNS: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy. The patient received 8 cycles of consolidation chemotherapy to maintain CR. In May 2017, the patient had recurrent ALL. Induction chemotherapy was given again, but without remission. In October 2017, CAR-T cell therapy was given. On October 14, the patient was pretreated with an FC regimen (fludarabine phosphate 50 mg qd on days 1–3; cyclophosphamide 0.4 g qd on days 1–3). CAR-T cells were infused on October 19 and October 20, with the number of infused cells at 2 × 10(5)/kg and 1 × 10(5)/kg, respectively. On October 25, the patient had a high fever, swelling, and pain in the large joints of the limbs, and joint effusion. DIAGNOSIS: This patient was diagnosed with relapsed ALL, and he developed CRS after CAR-T therapy. INTERVENTIONS: Tacilizumab (400 mg) was infused after CRS was diagnosed, and another dose of tacilizumab (240 mg) was given 6 days later. The pain was also treated with an analgesic drug. Methylprednisolone (1 mg/kg) was given to treat arthritis of the large joints. OUTCOMES: The patient's temperature was back to normal within 1 hour following the treatment of tacilizumab, but the pain in the large joints was progressively aggravated. The joint swelling and pain were obviously alleviated after the treatment of methylprednisolone, and the joint mobility was gradually recovered. LESSONS: CRS after CAR-T therapy can manifest as a high fever with swelling and pain in the large joints of the limbs, similar to rheumatoid arthritis. Tocilizumab can lower the body temperature, but it has no significant effect on arthritis. Glucocorticoids can rapidly alleviate joint swelling and pain.
format Online
Article
Text
id pubmed-5916644
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-59166442018-05-01 Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report Wang, Li-Xin Chen, Xiaoping Jia, Mingming Wang, Shengdian Shen, Jianliang Medicine (Baltimore) 4800 RATIONALE: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. PATIENT CONCERNS: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy. The patient received 8 cycles of consolidation chemotherapy to maintain CR. In May 2017, the patient had recurrent ALL. Induction chemotherapy was given again, but without remission. In October 2017, CAR-T cell therapy was given. On October 14, the patient was pretreated with an FC regimen (fludarabine phosphate 50 mg qd on days 1–3; cyclophosphamide 0.4 g qd on days 1–3). CAR-T cells were infused on October 19 and October 20, with the number of infused cells at 2 × 10(5)/kg and 1 × 10(5)/kg, respectively. On October 25, the patient had a high fever, swelling, and pain in the large joints of the limbs, and joint effusion. DIAGNOSIS: This patient was diagnosed with relapsed ALL, and he developed CRS after CAR-T therapy. INTERVENTIONS: Tacilizumab (400 mg) was infused after CRS was diagnosed, and another dose of tacilizumab (240 mg) was given 6 days later. The pain was also treated with an analgesic drug. Methylprednisolone (1 mg/kg) was given to treat arthritis of the large joints. OUTCOMES: The patient's temperature was back to normal within 1 hour following the treatment of tacilizumab, but the pain in the large joints was progressively aggravated. The joint swelling and pain were obviously alleviated after the treatment of methylprednisolone, and the joint mobility was gradually recovered. LESSONS: CRS after CAR-T therapy can manifest as a high fever with swelling and pain in the large joints of the limbs, similar to rheumatoid arthritis. Tocilizumab can lower the body temperature, but it has no significant effect on arthritis. Glucocorticoids can rapidly alleviate joint swelling and pain. Wolters Kluwer Health 2018-04-20 /pmc/articles/PMC5916644/ /pubmed/29668614 http://dx.doi.org/10.1097/MD.0000000000010455 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4800
Wang, Li-Xin
Chen, Xiaoping
Jia, Mingming
Wang, Shengdian
Shen, Jianliang
Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title_full Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title_fullStr Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title_full_unstemmed Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title_short Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
title_sort arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor t cell therapy: a case report
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916644/
https://www.ncbi.nlm.nih.gov/pubmed/29668614
http://dx.doi.org/10.1097/MD.0000000000010455
work_keys_str_mv AT wanglixin arthritisoflargejointsshownasarareclinicalfeatureofcytokinereleasesyndromeafterchimericantigenreceptortcelltherapyacasereport
AT chenxiaoping arthritisoflargejointsshownasarareclinicalfeatureofcytokinereleasesyndromeafterchimericantigenreceptortcelltherapyacasereport
AT jiamingming arthritisoflargejointsshownasarareclinicalfeatureofcytokinereleasesyndromeafterchimericantigenreceptortcelltherapyacasereport
AT wangshengdian arthritisoflargejointsshownasarareclinicalfeatureofcytokinereleasesyndromeafterchimericantigenreceptortcelltherapyacasereport
AT shenjianliang arthritisoflargejointsshownasarareclinicalfeatureofcytokinereleasesyndromeafterchimericantigenreceptortcelltherapyacasereport